Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Fulcrum Therapeutics, Inc. | President, Research & Development | Stock Option (right to buy) | 141K | Jan 19, 2022 | Direct | ||
Eliem Therapeutics, Inc. | Director | Stock Option (Right To Buy) | 10K | Jun 26, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ELYM | Eliem Therapeutics, Inc. | Jun 26, 2024 | 1 | $0 | 4 | Jun 28, 2024 | Director |
ELYM | Eliem Therapeutics, Inc. | May 18, 2023 | 1 | $0 | 4 | May 22, 2023 | Director |
ELYM | Eliem Therapeutics, Inc. | May 19, 2022 | 1 | $0 | 4 | Jun 1, 2022 | Director |
FULC | Fulcrum Therapeutics, Inc. | Jan 19, 2022 | 1 | $0 | 4 | Jan 21, 2022 | President, Research & Development |
ELYM | Eliem Therapeutics, Inc. | Aug 9, 2021 | 0 | $0 | 3 | Aug 9, 2021 | Director |